



Individuals with Scientific or Medical Training - Survey Feedback

Purpose: This document presents feedback submitted through the 2026 survey for individuals with scientific or medical training. The table reproduces the substantive survey information provided by respondents. Survey responses reflect the experience and opinions of individual respondents and have not been independently verified by PDAB. Blank survey items are shown as “No response.”

Humulin R U-500 concentrated (*insulin regular*)

Primary professional role	Healthcare profession involved in patient care
Years of experience treating or studying this condition	More than 10 years
Practice setting	Outpatient clinic
Typical role of this drug treatment	Later-line / refractory use
Patient population most commonly receiving this drug	Moderate
Is this drug clinically substitutable for at least one alternative?	Yes, for some patients
Compared to therapeutic alternatives, this drug provides	Substantial additional clinical benefit
Strength of evidence supporting use for its primary indication	High (multiple RCTs, guideline-supported)
Off-label use in your practice or system	Rare
Utilization management requirement typically associated with this drug (Select all that apply)	Step therapy; Quantity limits; completely unsustainable need for updating quant limit w.pharm due to ins requirements
Administrative burden relative to alternatives	Much higher
Does utilization management delay patient access	Frequently



In your experience, patient out-of-pocket costs for this drug are	FQHC
Have patients delayed or declined treatment due to cost?	Frequently
Impact of patient cost on adherence	Major negative impact
Are there other impacts that cause adherence issues?	The presence of and obstruction by even Medicaid and other insurances are barriers to patient care, contribute to provider burnout, create bottlenecks at pharmacies and cost patient lives, limbs, kidneys, families and are absolutely shameful and inappropriate and we need to have more DIRECT ACTION FOR UNIVERSAL HEALTHCARE NOW!
Availability of the drug when clinically needed	Occasionally delayed
If delays occur, primary cause	Supply shortages
Overall impact of this drug on health system costs	Increases costs substantially
Overall value of this drug relative to its cost	Moderate value
From a clinical perspective, does this drug contribute to affordability concerns for patients?	Yes
Is there anything else you would like PDAB to know about this medication?	We need (AND HAVE AVAILABLE) much more work toward prevention because a huge percentage of patients are on the med due to healthcare illiteracy and food deserts.
If you could change one thing about how this prescription drug is priced or accessed in Oregon, what would it be?	I'd reduce the need for it by diverting resources into health education, availability of better support for social determinants and better public health access